Insulin human
Also known as: Human insulin, Humulin, INS, Insulin human, Myxredlin, Novolin, Regular insulin
Source Insulin human at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Human insulin is a recombinant form of the pancreatic hormone used to replace deficient insulin in people with type 1 or type 2 diabetes. It is approved for subcutaneous, intramuscular and intravenous injection and, as the Technosphere® inhaled powder (Afrezza®), for rapid‑acting prandial therapy delivered via a breath‑powered inhaler. The product lowers blood glucose by providing the hormone that the body can no longer produce adequately.
Mechanism of Action
Human insulin binds to the insulin receptor on target cells, triggering autophosphorylation of the receptor and activation of intracellular pathways such as PI3K/Akt. This cascade promotes translocation of GLUT4 transporters to the cell surface, enhances glucose uptake, suppresses hepatic glucose production, and regulates protein and lipid metabolism, thereby reducing circulating glucose concentrations.
What the Research Shows
Early clinical work noted that improved insulin purity reduced antibody formation, yet some patients still develop antibodies that can alter insulin pharmacokinetics and cause post‑prandial hyperglycaemia or delayed hypoglycaemia. A systematic review of trials comparing human and animal insulin found no consistent evidence that human insulin changes hypoglycaemia frequency, although less rigorous studies suggested possible effects linked to tighter glycaemic control. The need for ultra‑fast prandial insulin led to the development of inhaled Technosphere insulin, which is absorbed from the alveoli and reaches systemic circulation faster than subcutaneous rapid‑acting analogues. Pre‑clinical safety studies in animals reported no insulin‑related adverse events, and clinical experience with over 13,000 patients showed tolerability despite higher antibody titres. Phase III trials of Afrezza demonstrated non‑inferior HbA1c lowering to subcutaneous aspart in type 1 diabetes and superior HbA1c reduction versus placebo in type 2 diabetes, with lower rates of hypoglycaemia, weight gain and a cough that was generally mild and transient. Expert commentary highlights rapid absorption, shorter duration of action, and the need for periodic lung function monitoring.
Reported Benefits
Human insulin provides essential hormone replacement, achieving glycaemic control comparable to other rapid‑acting formulations. The inhaled Technosphere version delivers insulin to the bloodstream within minutes, offering a more physiological post‑meal glucose profile and reducing the need for injections. Clinical trials report lower fasting glucose, less hypoglycaemia and reduced weight gain compared with some subcutaneous analogues, and many patients report improved treatment satisfaction, especially those with injection aversion.
Limitations of the Evidence
Antibody formation, although less common with modern preparations, can still modify insulin kinetics in some individuals. Evidence on whether human insulin per se increases hypoglycaemia risk is mixed and largely derived from lower‑quality studies. Inhaled insulin is associated with cough, mild transient reductions in forced expiratory volume, and is contraindicated in chronic lung disease; long‑term pulmonary safety, including lung‑cancer risk, remains under observation. Availability of animal‑derived insulin remains important for patients who cannot tolerate human insulin or have specific antibody issues.
Safety Considerations
The principal safety concern with any insulin is hypoglycaemia, which requires careful dose titration. Antibody‑mediated alterations in absorption may lead to post‑prandial hyperglycaemia or delayed hypoglycaemia. Inhaled Technosphere insulin commonly causes a dry cough and can produce a modest, reversible decline in lung function; periodic spirometry is recommended. Patients with chronic obstructive pulmonary disease, asthma, or recent lung infections should avoid inhaled insulin. No increased lung‑cancer incidence has been confirmed, but surveillance continues.
How It Is Administered
Human insulin is supplied as a sterile solution for subcutaneous, intramuscular or intravenous injection. The inhaled formulation is a dry powder (Technosphere) delivered by a breath‑powered oral inhaler that deposits insulin in the deep lung for rapid systemic absorption. Both routes require appropriate device handling and storage as indicated by the manufacturer.
Routes of Administration
Goals & Uses
- Gestational diabetes managementObstetricsHigh
- Glycemic control in type 2 diabetesMetabolicHigh
- Glycemic control in type 1 diabetesMetabolic / EndocrineHigh
- Glycemic control in type 1 diabetes mellitusEndocrine / MetabolicHigh
- Management of diabetic ketoacidosis (DKA)Emergency MedicineHigh
- Perioperative glucose controlSurgical / Critical CareHigh
- Hyperkalemia treatmentElectrolyte ManagementHigh
- Glycemic control in type 2 diabetes mellitusEndocrine / MetabolicHigh
Contraindications
- Hypokalemia (uncorrected)ElectrolyteModerate
- Hypersensitivity to insulin human or excipientsImmunologicHigh
- Hypersensitivity to insulin or excipientsAllergicModerate
- Hypoglycemia (active episode)MetabolicHigh
- HypoglycemiaMetabolicHigh
Adverse Effects
- HypokalemiaElectrolyteUncommon
- HypoglycemiaMetabolicCommonAbnormally low blood glucose
- Peripheral edemaFluid BalanceUncommonSwelling of the arms or legs
- Allergic reactionsImmunologicalRare
- Injection site reactions (lipohypertrophy, lipoatrophy)Local / DermatologicCommon
- Anaphylaxis / systemic allergyImmunologicRare
- Injection‑site reactionsLocalCommon
- Weight gainMetabolicCommonIncrease in body weight
Drug Interactions
- Thiazolidinediones (e.g., pioglitazone)Moderate
- Beta-blockers (non-selective)Moderate
- Beta‑blockersModerate
- Salicylates (high dose)Low
- AlcoholModerate
- CorticosteroidsModerate
- MAO inhibitorsModerate
- ACE inhibitorsLow
- Thiazide diureticsLow
Population Constraints
- PregnancyReproductive SafetyRelative
- Hepatic impairmentOrgan FunctionRelative
- Renal impairmentOrgan ImpairmentRelative
- Elderly patientsAgeRelative
- Pediatrics (<2 years)AgeRelative
- Pediatric patients (neonates)AgeRelative
Regulatory Status
- European UnionApprovedApproved: type 1 diabetes mellitus, type 2 diabetes mellitusEMA approval for recombinant human insulin products.
- United StatesApprovedApproved: type 1 diabetes mellitus, type 2 diabetes mellitus, gestational diabetesMultiple formulations approved by FDA.
- United KingdomApprovedApproved: type 1 diabetes mellitus, type 2 diabetes mellitusMHRA approved; same indications as EU.
Approved worldwide for type 1 and type 2 diabetes; multiple formulations (rapid, short, intermediate, long‑acting).
Evidence & Sources
- Journal ArticleModerateVan Haeften TW1989-01-01T00:00:00.000000Z
- Journal ArticleModerateMuchmore DB2017-01-01T00:00:00.000000Z
- Journal ArticleModerateWolff RK, Blanchard JD2025-01-01T00:00:00.000000Z
- Journal ArticleHighAirey CM, et al.2000-01-01T00:00:00.000000Z
- Journal ArticleModerateKim ES, Plosker GL2015-01-01T00:00:00.000000Z
- Journal ArticleModerateSetji TL, Hong BD, Feinglos MN2016-01-01T00:00:00.000000Z
Frequently Asked Questions
How does inhaled insulin differ from injected rapid‑acting insulin?
Inhaled Technosphere insulin is absorbed through the alveoli, reaching peak plasma concentrations within minutes, which is faster than subcutaneous rapid‑acting analogues. This results in a shorter duration of action and may reduce post‑meal hypoglycaemia, but it can cause cough and requires lung function monitoring.
Can patients develop resistance to human insulin?
Some patients develop insulin antibodies that can modestly alter insulin absorption and post‑prandial glucose levels. Modern highly purified human insulin reduces this risk, but antibody formation still occurs in a minority of individuals.
Is inhaled insulin safe for people with asthma?
Inhaled insulin is contraindicated in chronic lung diseases, including asthma, because it can cause cough and a temporary decline in forced expiratory volume. Patients with such conditions should use injectable insulin and undergo regular pulmonary assessment if inhaled therapy is considered.
Does human insulin cause weight gain?
Clinical trials of inhaled human insulin reported less weight gain compared with subcutaneous insulin aspart, likely due to lower overall insulin exposure and reduced hypoglycaemia‑related overeating. Injectable human insulin may still be associated with modest weight gain.
What monitoring is required when using inhaled insulin?
Patients should have baseline and periodic spirometry to detect any decline in lung function. Blood glucose monitoring remains essential to avoid hypoglycaemia, and clinicians should watch for persistent cough or respiratory symptoms.
What is Insulin human?
Human insulin is a recombinant form of the pancreatic hormone used to replace deficient insulin in people with type 1 or type 2 diabetes. It is approved for subcutaneous, intramuscular and intravenous injection and, as the Technosphere® inhaled powder (Afrezza®), for rapid‑acting prandial therapy delivered via a breath‑powered inhaler. The product lowers blood glucose by providing the hormone that the body can no longer produce adequately.
What is Insulin human used for?
Insulin human is educationally associated with: Gestational diabetes management, Glycemic control in type 2 diabetes, Glycemic control in type 1 diabetes, Glycemic control in type 1 diabetes mellitus, Management of diabetic ketoacidosis (DKA), Perioperative glucose control, Hyperkalemia treatment, Glycemic control in type 2 diabetes mellitus. Educational only — not medical advice.
How is Insulin human administered?
Recorded routes of administration: Inhalation, Intramuscular, Intravenous, Subcutaneous.
What are the potential side effects of Insulin human?
Reported adverse effects include: Hypokalemia, Hypoglycemia, Peripheral edema, Allergic reactions, Injection site reactions (lipohypertrophy, lipoatrophy), Anaphylaxis / systemic allergy, Injection‑site reactions, Weight gain. This list is not exhaustive — consult a qualified clinician.
Who should avoid Insulin human?
Recorded contraindications: Hypokalemia (uncorrected), Hypersensitivity to insulin human or excipients, Hypersensitivity to insulin or excipients, Hypoglycemia (active episode), Hypoglycemia. Consult a qualified clinician before use.